Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A2 | P43004 | 7/20 | 0.67 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.67 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2004125 | 1.00 | SLC1A2 (0.67) | SLC1A2SLC1A1SLC1A3KMT2AMEN1 | |
| SCHEMBL2000767 | 0.89 | SLC1A2 (0.63) | SLC1A2SLC1A1SLC1A3KMT2AMEN1 | |
| SCHEMBL418322 | 0.88 | SLC1A3 (0.76) | SLC1A2SLC1A1SLC1A3KMT2AMEN1 | |
| SCHEMBL1953602 | 0.88 | SLC1A3 (0.76) | SLC1A2SLC1A1SLC1A3KMT2AMEN1 | |
| SCHEMBL852209 | 0.88 | SLC1A3 (0.76) | SLC1A2SLC1A1SLC1A3KMT2AMEN1 | |
| SCHEMBL8840019 | 0.87 | SLC1A2 (0.65) | SLC1A2SLC1A1SLC1A3KMT2AMEN1 | |
| Water SCHEMBL30419716 | 0.86 | SLC1A3 (0.73) | SLC1A2SLC1A1SLC1A3KMT2AMEN1 | |
| SCHEMBL828782 | 0.86 | SLC1A3 (0.54) | SLC1A2SLC1A1SLC1A3KMT2AMEN1 | |
| SCHEMBL824885 | 0.86 | SLC1A3 (0.54) | SLC1A2SLC1A1SLC1A3KMT2AMEN1 | |
| SCHEMBL6062626 | 0.85 | SLC1A3 (0.51) | SLC1A2SLC1A1SLC1A3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| US-10934244-B2 | Compounds for use in treating neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-03-02 | — | — | US | disclosed |
| US-10385028-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2019-08-20 | — | — | US | disclosed |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190185437-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA APS | 2019-06-20 | — | — | US | disclosed |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA APS (DK) | 2018-04-12 | — | — | US | disclosed |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA APS (DK) | 2018-04-12 | — | — | US | disclosed |
| US-7960420-B2 | Diazonamide analogs with improved solubility | JOYANT PHARMACEUTICALS, INC (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960420-B2 | Diazonamide analogs with improved solubility | JOYANT PHARMACEUTICALS, INC (US) | 2011-06-14 | — | — | US | disclosed |
| WO-2009086170-A1 | DIAZONAMIDE ANALOGS WITH IMPROVED SOLUBILITY | JOYANT PHARMACEUTICALS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163446-A1 | DIAZONAMIDE ANALOGS WITH IMPROVED SOLUBILITY | JOYANT PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163446-A1 | DIAZONAMIDE ANALOGS WITH IMPROVED SOLUBILITY | JOYANT PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | SLC1A2 125/4885SLC1A1 85/4885SLC1A3 107/4885 |
| US-10934244-B2 | Compounds for use in treating neuromuscular disorders | CPT1B, CLCN2, TNNC1 | SLC1A2 68/4885SLC1A1 71/4885SLC1A3 81/4885 |
| US-20090163446-A1 | DIAZONAMIDE ANALOGS WITH IMPROVED SOLUBILITY | PKD1, PKD2, GLS | SLC1A2 1270/4885SLC1A1 924/4885SLC1A3 347/4885 |
| US-20190183834-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | SLC1A2 125/4885SLC1A1 85/4885SLC1A3 107/4885 |
| US-20190185409-A1 | Compounds For The Treatment Of Neuromuscular Disorders | CPT1B, CLCN2, CACNB1 | SLC1A2 80/4885SLC1A1 35/4885SLC1A3 33/4885 |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | CPT1B, CLCN2, TNNC1 | SLC1A2 68/4885SLC1A1 71/4885SLC1A3 81/4885 |
| US-20190183812-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | SLC1A2 125/4885SLC1A1 85/4885SLC1A3 107/4885 |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | SLC1A2 125/4885SLC1A1 85/4885SLC1A3 107/4885 |
| US-10385028-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | SLC1A2 125/4885SLC1A1 85/4885SLC1A3 107/4885 |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | SLC1A2 125/4885SLC1A1 85/4885SLC1A3 107/4885 |
| US-20190185437-A1 | Compounds For The Treatment Of Neuromuscular Disorders | CLCN2, SCN1B, CACNB1 | SLC1A2 56/4885SLC1A1 37/4885SLC1A3 40/4885 |
| US-20190183833-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | SLC1A2 125/4885SLC1A1 85/4885SLC1A3 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.